The most researched peptide for tissue healing — over 100 preclinical studies but no FDA approval.
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide derived from a sequence found in human gastric juice protein BPC. It was discovered by researcher Dijen Sikiric and colleagues at the University of Zagreb, where it has been extensively studied for over three decades. The '157' refers to its molecular weight and sequence position.
BPC-157 acts through multiple mechanisms: it promotes angiogenesis (new blood vessel formation), accelerates collagen synthesis, modulates nitric oxide (NO) production, upregulates growth factor receptors (including VEGFR2 and EGF receptors), and demonstrates anti-inflammatory effects in various tissues. This broad mechanism explains why it appears to accelerate healing across diverse tissue types — tendon, ligament, muscle, bone, gut, and nerve.
Despite extraordinary preclinical evidence — over 100 peer-reviewed studies in rodent models — BPC-157 has not completed human Phase 3 clinical trials and is not FDA-approved for any indication. It was placed on the FDA's list of Bulk Drug Substances Under Evaluation in 2022 (Section 503B), meaning its use in compounding was under regulatory scrutiny. Patients should understand this distinction between promising preclinical data and clinical validation.
Animal research demonstrates BPC-157 accelerates healing of tendons (including the Achilles and patellar tendons), ligaments, muscles, bones, and the GI tract. Mechanisms studied include upregulation of tendon fibroblast migration, angiogenesis near injury sites, and growth factor receptor expression. PMID: 24175929, PMID: 12499251, PMID: 28853221 document key preclinical findings.
Gastrointestinal research is particularly robust — BPC-157 protects against NSAID-induced gut damage, heals gastric ulcers, and appears to counter alcohol-induced GI injury in animal models. This has led to interest in oral BPC-157 formulations. However, human clinical trial data remains limited. A Phase 2 trial for inflammatory bowel disease was conducted in 1990s Croatia; no peer-reviewed Phase 3 data exists.
📚 Key Reference: PMID: 24175929 (tendon healing), PMID: 12499251 (gastric protection), PMID: 28853221 (muscle healing)
BPC-157 has demonstrated a very favorable safety profile in all preclinical studies — no LD50 has been established (cannot establish a toxic dose). No significant adverse events in limited human exposure data. The main patient concern is the regulatory status: as of 2022-2024, its status in compounding has been under FDA review. Patients should ensure any BPC-157 comes from a licensed 503A/503B compounding pharmacy with Certificates of Analysis. Do not purchase from research chemical suppliers. Always consult your provider.
NOT FDA-approved. Listed on FDA's 503B Bulk Drug Substance list under evaluation (Category 2 — nominated but not yet placed on approved or prohibited list as of 2024). Available through compounding pharmacies under medical supervision. Regulatory status should be verified with your provider as FDA guidance evolves.